Tiludronate infusion in horses previously submitted to bone scintigraphy

This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the stu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dörner,CA, Rick,MC, Judy,CE
Lenguaje:English
Publicado: Facultad de Ciencias Veterinarias, Universidad Austral de Chile 2016
Materias:
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0301-732X2016000300010
record_format dspace
spelling oai:scielo:S0301-732X20160003000102016-12-27Tiludronate infusion in horses previously submitted to bone scintigraphyDörner,CARick,MCJudy,CE horse bisphosphonates tiludronate bone scintigraphy This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the study. Fifteen horses received a dose of technetium (0.3 mCi/kg), MDP (20 mg; medronate) and another fifteen horses received technetium (0.3 mCi/kg), MDP (20 mg), and furosemide (1 mg/kg). Then, 24 to 36 hours after the bone scintigraphy, eight horses were selected and received tiludronate (500 mg in 5L of 0.9% NaCl). Blood samples were collected 15 minutes prior, 24 and 48 hours after the treatment and a chemistry panel was assayed on the day of collection. Serum chemistry values were not significantly different between horses receiving tiludronate and those in both control groups. Additionally, one horse showed mild transient signs of colic recorded as pacing and stretching in the stall after 3 hours the injection of the tiludronic acid. The results suggest that tiludronate can be administered safely as one single dose in horses having undergone recent bone scintigraphy without additional complications or detrimental effect other than those previously described for the drug.info:eu-repo/semantics/openAccessFacultad de Ciencias Veterinarias, Universidad Austral de ChileArchivos de medicina veterinaria v.48 n.3 20162016-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010en10.4067/S0301-732X2016000300010
institution Scielo Chile
collection Scielo Chile
language English
topic horse
bisphosphonates
tiludronate
bone scintigraphy
spellingShingle horse
bisphosphonates
tiludronate
bone scintigraphy
Dörner,CA
Rick,MC
Judy,CE
Tiludronate infusion in horses previously submitted to bone scintigraphy
description This study was performed to evaluate the systemic short-term effects of tiludronate intravenous infusion on serum biochemical variables when administered as one single-dose in horses that undergo bone scintigraphy within 24 to 36 hours prior to treatment. Thirty-eight horses were enrolled in the study. Fifteen horses received a dose of technetium (0.3 mCi/kg), MDP (20 mg; medronate) and another fifteen horses received technetium (0.3 mCi/kg), MDP (20 mg), and furosemide (1 mg/kg). Then, 24 to 36 hours after the bone scintigraphy, eight horses were selected and received tiludronate (500 mg in 5L of 0.9% NaCl). Blood samples were collected 15 minutes prior, 24 and 48 hours after the treatment and a chemistry panel was assayed on the day of collection. Serum chemistry values were not significantly different between horses receiving tiludronate and those in both control groups. Additionally, one horse showed mild transient signs of colic recorded as pacing and stretching in the stall after 3 hours the injection of the tiludronic acid. The results suggest that tiludronate can be administered safely as one single dose in horses having undergone recent bone scintigraphy without additional complications or detrimental effect other than those previously described for the drug.
author Dörner,CA
Rick,MC
Judy,CE
author_facet Dörner,CA
Rick,MC
Judy,CE
author_sort Dörner,CA
title Tiludronate infusion in horses previously submitted to bone scintigraphy
title_short Tiludronate infusion in horses previously submitted to bone scintigraphy
title_full Tiludronate infusion in horses previously submitted to bone scintigraphy
title_fullStr Tiludronate infusion in horses previously submitted to bone scintigraphy
title_full_unstemmed Tiludronate infusion in horses previously submitted to bone scintigraphy
title_sort tiludronate infusion in horses previously submitted to bone scintigraphy
publisher Facultad de Ciencias Veterinarias, Universidad Austral de Chile
publishDate 2016
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0301-732X2016000300010
work_keys_str_mv AT dornerca tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy
AT rickmc tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy
AT judyce tiludronateinfusioninhorsespreviouslysubmittedtobonescintigraphy
_version_ 1718437970683363328